DeepMed Research

FibroGen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1993-01-01

Employees: 486

Market Cap: $38.6M

Website: http://www.fibrogen.com

Clinical Trials

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Phase 3

Completed

Conditions: Anemia in Incident Dialysis Patients

Interventions: Drug: Epoetin Alfa
Drug: Roxadustat

First Posted Date: 2014-02-03

Last Posted Date: 2021-10-01

Lead Sponsor: FibroGen

Target Recruit Count: 1043

Registration Number: NCT02052310

Locations: 🇧🇬
Invesigational Site, Stara Zagora, Bulgaria
🇷🇺
Investigational site, St. Petersburg, Russian Federation
🇺🇸
Meridian, Meridian, Idaho, United States

and more 5 locations

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pamrevlumab

First Posted Date: 2013-07-01

Last Posted Date: 2020-09-04

Lead Sponsor: FibroGen

Target Recruit Count: 160

Registration Number: NCT01890265

Locations: 🇺🇸
Pensacola Research Consultants, Inc., d.b.a. Avanza Medical Research Center, Pensacola, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇦🇺
Concord Repatriation, Concord, New South Wales, Australia

and more 39 locations

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

Phase 3

Completed

Conditions: CKD Anemia

Interventions: Drug: Placebo
Drug: Roxadustat

First Posted Date: 2012-12-17

Last Posted Date: 2021-10-01

Lead Sponsor: FibroGen

Target Recruit Count: 922

Registration Number: NCT01750190

Locations: 🇦🇷
Investigational Product, Villa Domínico, Provincia De Buenos Aires, Argentina
🇹🇭
Investigational Site, Chiang Mai, Thailand
🇵🇭
Investigational site, Pasig, Philippines

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Disease
End Stage Renal Disease
Anemia

Interventions: Drug: Roxadustat

First Posted Date: 2012-06-28

Last Posted Date: 2021-10-01

Lead Sponsor: FibroGen

Target Recruit Count: 15

Registration Number: NCT01630889

Locations: 🇵🇷
CAIMED School of Medicine, Ponce, Puerto Rico
🇵🇷
Consolidated Medical Plaza, Caguas, Puerto Rico
🇺🇸
Mountain Kidney & HTN Associates, PA, Asheville, North Carolina, United States

and more 2 locations

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

Phase 2

Completed

Conditions: Anemia in Chronic Kidney Disease

Interventions: Drug: FG-4592
Drug: Placebo

First Posted Date: 2012-05-16

Last Posted Date: 2014-03-03

Lead Sponsor: FibroGen

Target Recruit Count: 91

Registration Number: NCT01599507

Locations: 🇨🇳
First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
🇨🇳
West China Hospital, Chengdu, China
🇨🇳
First affiliated hospital of Dalian medical university, DaLian, China

and more 10 locations

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Phase 2

Completed

Conditions: Anemia in End Stage Renal Disease

Interventions: Drug: FG-4592
Drug: Epoetin Alfa

First Posted Date: 2012-05-11

Last Posted Date: 2013-02-04

Lead Sponsor: FibroGen

Target Recruit Count: 96

Registration Number: NCT01596855

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Chang Zheng Hospital, Shanghai, China
🇨🇳
RuiJin Hospital, Shanghai, China

and more 6 locations

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Phase 2

Completed

Conditions: Dialysis
Anemia

Interventions: Drug: Roxadustat
Drug: IV Iron
Drug: Oral Iron

First Posted Date: 2011-08-11

Last Posted Date: 2021-10-01

Lead Sponsor: FibroGen

Target Recruit Count: 60

Registration Number: NCT01414075

Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: FG-4592

First Posted Date: 2011-06-20

Last Posted Date: 2011-06-20

Lead Sponsor: FibroGen

Target Recruit Count: 20

Registration Number: NCT01376063

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: FG-3019

First Posted Date: 2010-12-17

Last Posted Date: 2019-10-09

Lead Sponsor: FibroGen

Target Recruit Count: 90

Registration Number: NCT01262001

Locations: 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States

and more 15 locations

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Phase 2

Completed

Conditions: Chronic Kidney Disease
Anemia

Interventions: Drug: Roxadustat

First Posted Date: 2010-11-19

Last Posted Date: 2022-02-10

Lead Sponsor: FibroGen

Target Recruit Count: 145

Registration Number: NCT01244763

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy